Clinical Pharmacokinetics and Pharmacodynamics of Etravirine

Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. It has a high genetic barrier to the emergence of viral resistance, and maintains its antiviral activity in the presence of common NNRTI mutations. The pharmacokinetics of etravirine in HIV-infected patients at the recommended dosage of 200 mg twice daily demonstrates moderate intersubject variability and no time dependency. Due to substantially lower exposures when taken on an empty stomach, etravirine should be administered following a meal. The drug is highly protein bound (99.9%) to albumin and α1-acid glycoprotein and shows a relatively long elimination half-life of 30–40 hours. Etravirine is metabolized by cytochrome P450 (CYP) 3A, 2C9 and 2C19; the metabolites are subsequently glucuronidated by uridine diphosphate glucuronosyltransferase. Renal elimination of etravirine is negligible. Etravirine has the potential for interactions by inducing CYP3A and inhibiting CYP2C9 and 2C19; it is a mild inhibitor of P-glycoprotein but not a substrate. The drug interaction profile of etravirine has been well characterized and is manageable. No dosage adjustments are needed in patients with renal impairment or mild to moderate hepatic impairment. Race, sex, bodyweight and age do not affect the pharmacokinetics of etravirine. In the two phase III trials DUET-1 and DUET-2, no relationship was demonstrated between the pharmacokinetics of etravirine and the primary efficacy endpoint of viral load below 50 copies/mL or the safety profile of etravirine.

[1]  R. Haubrich,et al.  The impact of baseline characteristics on virologic response to etravirine: 48-week pooled analysis of DUET-1 and DUET-2 , 2010 .

[2]  J. Wagner,et al.  Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects , 2008, Antimicrobial Agents and Chemotherapy.

[3]  M. Peeters,et al.  Pharmacokinetics of Darunavir/Ritonavir and TMC125 alone and Coadministered in HIV-Negative Volunteers , 2007, Antiviral therapy.

[4]  M. Peeters,et al.  Pharmacokinetics (PK) and Pharmacodynamics (PD) of Etravirine (ETR) in Treatment-Experienced HIV-1 Infected Patients: Pooled 48-Week Results of DUET-1 and DUET-2 , 2008 .

[5]  D. Marriott,et al.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. , 2005, British journal of clinical pharmacology.

[6]  C. Katlama,et al.  Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients , 2008 .

[7]  M. Peeters,et al.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. , 2008, British journal of clinical pharmacology.

[8]  M. Peeters,et al.  Etravirine Has No Effect on QT and Corrected QT Interval in HIV-Negative Volunteers , 2008, The Annals of pharmacotherapy.

[9]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[10]  R. Haubrich,et al.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.

[11]  W. G. Nichols,et al.  Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. , 2009, The Journal of antimicrobial chemotherapy.

[12]  B. Kearney,et al.  Pharmacokinetics of Elvitegravir and Etravirine following Coadministration of Ritonavir-Boosted Elvitegravir and Etravirine , 2008, Antiviral therapy.

[13]  D. Breilh,et al.  Virological Responses to Atazanavir–Ritonavir-Based Regimens: Resistance-Substitutions Score and Pharmacokinetic Parameters (Reyaphar Study) , 2005, Antiviral therapy.

[14]  E. Sellers,et al.  Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail” , 2003, Clinical pharmacology and therapeutics.

[15]  A. Lazzarin,et al.  Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. , 2007, The new microbiologica.

[16]  Koen Andries,et al.  TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[17]  V. Vyncke,et al.  Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine , 2008, Pharmacotherapy.

[18]  G. Beets,et al.  Assessment of the steady‐state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers , 2009, HIV medicine.

[19]  M. Shelton,et al.  Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and Ritonavir , 2006, Antimicrobial Agents and Chemotherapy.

[20]  A. Pozniak,et al.  Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients , 2008, Antiviral therapy.

[21]  P. Colson,et al.  The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected Treatment-Experienced Patients , 2008, Journal of acquired immune deficiency syndromes.

[22]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[23]  Basia Zaba,et al.  Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. , 2007, AIDS.

[24]  F. de Wolf,et al.  Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. , 2007, The Journal of antimicrobial chemotherapy.

[25]  D. Ward,et al.  Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis , 2007, AIDS.